# SYTL4

## Overview
SYTL4, or synaptotagmin-like 4, is a gene that encodes a protein involved in intracellular trafficking and exocytosis, particularly in the context of vesicle transport within cells. The protein, categorized as a vesicle trafficking protein, plays a critical role in processes such as insulin granule exocytosis in pancreatic beta cells and platelet secretion, which are essential for metabolic regulation and hemostasis, respectively (Adam2018Kinesin1; Liu2020SYTL4). SYTL4 interacts with Rab GTPases and microtubules, influencing microtubule dynamics and stability, and is implicated in the secretion of extracellular vesicles in certain cancers (Liu2020SYTL4; Liao2020Epstein‐Barr). Its clinical significance is highlighted by its association with chemoresistance in triple-negative breast cancer and its potential as a neoantigen in melanoma, making it a target of interest for therapeutic interventions (BassaniSternberg2016Direct; Liu2020SYTL4).

## Function
SYTL4 (synaptotagmin-like 4) is involved in intracellular trafficking and exocytosis, playing a crucial role in the transport of vesicles within cells. It interacts with Rab GTPases, which are essential for vesicle docking and fusion at the plasma membrane, processes vital for maintaining cellular homeostasis and metabolic regulation. In particular, SYTL4 is implicated in the regulation of insulin granule exocytosis in pancreatic beta cells, highlighting its importance in metabolic processes (Liu2020SYTL4).

In the context of platelet function, SYTL4, also known as Slp4 or granuphilin, is involved in the molecular machinery that controls granule-membrane docking events. It interacts with Rab27a/b, small GTPases that are critical for platelet secretion, a process essential for hemostasis and thrombosis (Adam2018Kinesin1). SYTL4 is strongly expressed in platelets and megakaryocytes, and its interaction with kinesin-1 and Rab27b forms a complex that is crucial for platelet secretion and thrombus stability (Adam2018Kinesin1).

SYTL4's role in these processes underscores its significance in cellular and organismal functions, particularly in the regulation of secretion and maintenance of cellular homeostasis.

## Clinical Significance
SYTL4 has been implicated in various diseases and conditions due to mutations and alterations in its expression. In triple-negative breast cancer (TNBC), high expression of SYTL4 is associated with chemoresistance, particularly to the chemotherapy drug paclitaxel. Studies have shown that SYTL4 downregulates microtubule stability, which is crucial for the cytotoxic effects of paclitaxel, thereby contributing to drug resistance. Knockdown of SYTL4 in TNBC cell lines increases sensitivity to paclitaxel, suggesting its potential as a therapeutic target to overcome chemoresistance (Liu2020SYTL4).

In melanoma, the SYTL4 S363F mutation has been identified as a significant neoantigen capable of eliciting strong T-cell responses. This mutation is recognized by tumor-infiltrating lymphocytes, indicating its role in immune evasion and potential as a target for immunotherapy (BassaniSternberg2016Direct).

Additionally, a hemizygous c.164G>T (p.(Ser55Ile)) variant in SYTL4 has been identified in a family with inherited retinal disease. This variant affects a highly conserved serine in the Rab binding domain, potentially disrupting protein interactions, although its clinical significance requires further investigation (Astuti2018Identification).

## Interactions
SYTL4 (synaptotagmin-like 4) is known to interact with microtubules, playing a significant role in microtubule dynamics. This interaction is mediated through its linker-C2A domain, which is responsible for binding to the microtubule cytoskeleton. SYTL4's interaction with microtubules affects their stability, with its knockdown leading to increased tubulin acetylation and enhanced microtubule stability, while its overexpression decreases these effects (Liu2020SYTL4).

In the context of nasopharyngeal carcinoma, SYTL4 is involved in extracellular vesicle (EV) secretion. It acts as an effector molecule of RAB27A, promoting the fusion of vesicles with cell membranes, which facilitates EV release. Knockdown of SYTL4 results in the accumulation of multivesicular bodies inside cells, indicating its crucial role in mediating the fusion of these bodies with the cell membrane (Liao2020Epstein‐Barr).

SYTL4 is also associated with EFhd2 in the brain, where it is involved in vesicle trafficking. This interaction suggests a role for SYTL4 in mediating vesicle docking and fusion through the SNARE complex, although direct interactions with vesicle trafficking proteins have not been confirmed (Soliman2021EFhd2).


## References


[1. (BassaniSternberg2016Direct) Michal Bassani-Sternberg, Eva Bräunlein, Richard Klar, Thomas Engleitner, Pavel Sinitcyn, Stefan Audehm, Melanie Straub, Julia Weber, Julia Slotta-Huspenina, Katja Specht, Marc E. Martignoni, Angelika Werner, Rüdiger Hein, Dirk H. Busch, Christian Peschel, Roland Rad, Jürgen Cox, Matthias Mann, and Angela M. Krackhardt. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nature Communications, November 2016. URL: http://dx.doi.org/10.1038/ncomms13404, doi:10.1038/ncomms13404. This article has 565 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms13404)

[2. (Liu2020SYTL4) Xi-Yu Liu, Wang Jiang, Ding Ma, Li-Ping Ge, Yun-Song Yang, Zong-Chao Gou, Xiao-En Xu, Zhi-Ming Shao, and Yi-Zhou Jiang. Sytl4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer. Theranostics, 10(24):10940–10956, 2020. URL: http://dx.doi.org/10.7150/thno.45207, doi:10.7150/thno.45207. This article has 21 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7150/thno.45207)

[3. (Adam2018Kinesin1) Frédéric Adam, Alexandre Kauskot, Mathieu Kurowska, Nicolas Goudin, Isabelle Munoz, Jean-Claude Bordet, Jian-Dong Huang, Marijke Bryckaert, Alain Fischer, Delphine Borgel, Geneviève de Saint Basile, Olivier D. Christophe, and Gaël Ménasché. Kinesin-1 is a new actor involved in platelet secretion and thrombus stability. Arteriosclerosis, Thrombosis, and Vascular Biology, 38(5):1037–1051, May 2018. URL: http://dx.doi.org/10.1161/atvbaha.117.310373, doi:10.1161/atvbaha.117.310373. This article has 18 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1161/atvbaha.117.310373)

[4. (Astuti2018Identification) Galuh Astuti, L. Van den Born, M. Khan, Christian Hamel, Béatrice Bocquet, Gaël Manes, Mathieu Quinodoz, Manir Ali, Carmel Toomes, Martin McKibbin, Mohammed El-Asrag, Lonneke Haer-Wigman, Chris Inglehearn, Graeme Black, Carel Hoyng, Frans Cremers, and Susanne Roosing. Identification of inherited retinal disease-associated genetic variants in 11 candidate genes. Genes, 9(1):21, January 2018. URL: http://dx.doi.org/10.3390/genes9010021, doi:10.3390/genes9010021. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/genes9010021)

[5. (Liao2020Epstein‐Barr) Chaoliang Liao, Qin Zhou, Zhibao Zhang, Xia Wu, Zhuan Zhou, Bo Li, Jinwu Peng, Liangfang Shen, Dan Li, Xiangjian Luo, and Lifang Yang. Epstein‐barr virus‐encoded latent membrane protein 1 promotes extracellular vesicle secretion through syndecan‐2 and synaptotagmin‐like‐4 in nasopharyngeal carcinoma cells. Cancer Science, 111(3):857–868, February 2020. URL: http://dx.doi.org/10.1111/cas.14305, doi:10.1111/cas.14305. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/cas.14305)

[6. (Soliman2021EFhd2) Ahlam S. Soliman, Andrew Umstead, Tessa Grabinski, Nicholas M. Kanaan, Andy Lee, John Ryan, Jared Lamp, and Irving E. Vega. Efhd2 brain interactome reveals its association with different cellular and molecular processes. Journal of Neurochemistry, 159(6):992–1007, October 2021. URL: http://dx.doi.org/10.1111/jnc.15517, doi:10.1111/jnc.15517. This article has 4 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/jnc.15517)